In view of the comprehensive regulatory role of MAP3K8 in tumor immunity, therapeutic regimen blocking MAP3K8 might be a promising strategy for the development of more integrative and specific cancer immunotherapy for glioma. This evidence concerns the gene MAP3K8 and central nervous system cancer.